Karyopharm Therapeutics, Inc.

Karyopharm Therapeutics Inc. (KPTI) Accused of Misleading Investors

According to the complaint, in March 2017, Karyopharm reported that its interim results from its SORPA study of selinexor did not reach statistical significance for overall survival among AML patients, the primary endpoint of the study. As a result, Karyopharm halted the trial, but assured investors that there were “no new clinically significant adverse events in the patients receiving selinexor.” Throughout the relevant period, Karyopharm continued to tout the safety and commercial prospects of selixinor, assuring that it was “well tolerated” by patients. Despite these material misrepresentations and omissions, the truth was finally revealed on February 22, 2019, when the FDA released a briefing document expressing serious concerns about the safety of selixinor, stating in relevant part that the SORPA trial’s results actually showed “worse overall survival” for patients due to its toxicity, giving it limited efficacy. On this news, Karyopharm’s stock price declined $3.90, or more than 43% to close at $5.07.

Karyopharm Therapeutics Inc. (KPTI) Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can send us a message via the Shareholder Information below.

Send us a message for more information.

Protect your investments.

Sign up for free investment monitoring.

Stock Watch members receive free investment monitoring and notifications.  

Leave your details to get started